CardiNor Leads The Charge As Norway Gets Behind Life Sciences

Norwegian start-up CardiNor is developing a new cardiovascular biomarker, and is hopeful of attracting cash in a country where investor traditions are undergoing some changes. The financial pressures caused by falling oil prices have brought renewed attention to life science companies.

A significant economic milestone was passed by the small European nation of Norway two years ago. In January 2014, the central bank’s sovereign wealth fund exceeded NKr5.1 trillion (some $828 billion) for the first time. That made each person in Norway’s 5.1 million population a Krone millionaire. On paper, at least.

Held in reserve for future generations, the fund has increased in value at exponential rates since the country struck North Sea oil in 1969

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo